KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Assets Average (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Assets Average for 15 consecutive years, with $4.9 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets Average rose 16.26% year-over-year to $4.9 billion, compared with a TTM value of $4.9 billion through Dec 2025, up 16.26%, and an annual FY2025 reading of $4.6 billion, up 14.08% over the prior year.
  • Assets Average was $4.9 billion for Q4 2025 at Alnylam Pharmaceuticals, up from $4.7 billion in the prior quarter.
  • Across five years, Assets Average topped out at $4.9 billion in Q4 2025 and bottomed at $3.3 billion in Q1 2021.
  • Average Assets Average over 5 years is $3.8 billion, with a median of $3.6 billion recorded in 2021.
  • The sharpest move saw Assets Average skyrocketed 42.52% in 2021, then decreased 1.96% in 2023.
  • Year by year, Assets Average stood at $3.6 billion in 2021, then decreased by 0.48% to $3.5 billion in 2022, then increased by 8.29% to $3.8 billion in 2023, then grew by 10.12% to $4.2 billion in 2024, then rose by 16.26% to $4.9 billion in 2025.
  • Business Quant data shows Assets Average for ALNY at $4.9 billion in Q4 2025, $4.7 billion in Q3 2025, and $4.4 billion in Q2 2025.